Copy Link Print Information

Zodasiran

(Synonyms: ARO-ANG3)
Customer Review

Based on 1 Customer Validation

Zodasiran (ARO-ANG3) is an siRNA targeting ANGPTL3 that mediates RNAi degradation of ANGPTL3 mRNA, reducing hepatic ANGPTL3 protein synthesis and mRNA expression. Zodasiran can be used in research related to diseases such as atherosclerotic cardiovascular disease and mixed dyslipidemia.

For research use only. We do not sell to patients.

  • Purity : 95.26%
  • CAS No.: 2232918-66-8
  • Formula: C491H646F13N162O309P43S7
  • Molecular Weight:15564.70
  • Storage:

    -20°C, sealed storage, away from moisture

    * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

  • Zodasiran Chemical Structure
    Zodasiran Chemical Structure
CAS No.: 2232918-66-8
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Protocols
  • Purity & Documentation
  • References
  • Help & FAQs
Top Publications Citing

Use of MCE Products

All ANGPTL Isoforms

More

Keywords

MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Zodasiran Chemical Structure
    Zodasiran Chemical Structure RNA, ([1'-de(6-amino-9H-purin-9-yl)]dA-(5'→5')-sp-Gm-Cm-Um-Cm-Am-Am-Cm-Am-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)A-(2'-deoxy-2'-fluoro)U-Um-Um-Gm-Am-Um-Cm-Am-Gm-Um-Am-(3'→3')-sp-[1'-de(6-amino-9H-purin-9-yl)]dA), 3'-[O-[cis-4-[(3S,8S)-17-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-3,8-bis[[[2-[2-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]ethoxy]ethyl]amino]carbonyl]-1,6,11-trioxo-15-oxa-2,7,12-triazaheptadec-1-yl]cyclohexyl] hydrogen phosphorothioate], complex with RNA (Um-sp-(2'-deoxy-2'-fluoro)A-sp-Cm-sp-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'-fluoro)A-Um-(2'-deoxy-2'-fluoro)C-Am-(2'-deoxy-2'-fluoro)A-Am-(2'-deoxy-2'-fluoro)U-Am-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'-fluoro)U-Um-(2'-deoxy-2'-fluoro)G-Am-(2'-deoxy-2'-fluoro)G-sp-Cm) (1:1)
    1/16
  • RNA, ([1'-de(6-amino-9H-purin-9-yl)]dA-(5'→5')-sp-Gm-Cm-Um-Cm-Am-Am-Cm-Am-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)A-(2'-deoxy-2'-fluoro)U-Um-Um-Gm-Am-Um-Cm-Am-Gm-Um-Am-(3'→3')-sp-[1'-de(6-amino-9H-purin-9-yl)]dA), 3'-[O-[cis-4-[(3S,8S)-17-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-3,8-bis[[[2-[2-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]ethoxy]ethyl]amino]carbonyl]-1,6,11-trioxo-15-oxa-2,7,12-triazaheptadec-1-yl]cyclohexyl] hydrogen phosphorothioate], complex with RNA (Um-sp-(2'-deoxy-2'-fluoro)A-sp-Cm-sp-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'-fluoro)A-Um-(2'-deoxy-2'-fluoro)C-Am-(2'-deoxy-2'-fluoro)A-Am-(2'-deoxy-2'-fluoro)U-Am-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'-fluoro)U-Um-(2'-deoxy-2'-fluoro)G-Am-(2'-deoxy-2'-fluoro)G-sp-Cm) (1:1)